Estimated Worldwide Prevalence of the PI*ZZ Alpha-1 Antitrypsin Genotype in Subjects With Chronic Obstructive Pulmonary Disease
Arch. bronconeumol. (Ed. impr.)
; 59(7): 427-434, jul. 2023. mapas, tab
Artigo
em Inglês
| IBECS
| ID: ibc-223088
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Introduction:
The prevalence of α1-antitrypsin PI*ZZ genotypes in patients with COPD is only partially known. We aimed to estimate this prevalence worldwide.Method:
A systematic review of the literature was conducted for studies investigating the prevalence of COPD and the prevalence of severe alpha-1-antitrypsin deficiency (AATD) PI*ZZ genotype. Results are shown in tables and on a whole world interpolation map.Results:
Studies from 48 countries with available data (21 from Europe, 9 from the Americas, 5 from Africa, 11 from Asia and 2 from Australasia) were selected. About 235,000 individuals with PI*ZZ genotypes were accounted 50% in Europe, 37% in America, 9% in Asia, 3% in Australasia and 1% in Africa. The estimated crude prevalence of COPD in adults older than 40 years was 12.45% in Europe, 13.51% in America, 13.22% in Africa, 11.70% in Asia and 11.86% in Australasia. The highest PI*ZZ weighted average prevalence among COPD subjects (expressed as 1/x [95% confidence intervals]) were found in Northern Europe (395 [252576]) followed by Western (797 [5381165]), Southern (944 [6001475]) and Central Europe (1096 [6871738]). Outside Europe, high values were found in AustraliaNew Zealand (1007 [6841509]), Saudi Arabia (1276 [5632961]), United States (1298 [10941540]), Canada (1482 [10572083]) and Thailand (1807 [7174692]). In the rest of the world, prevalence was significantly lower, especially in vast regions of Asia and Africa where the PI*Z gene is practically non-existent.Conclusions:
Severe AATD is associated with a significant number of cases of COPD, especially in Europe, USA, Canada, New Zealand and Australia. (AU)
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Deficiência de alfa 1-Antitripsina
/
Doença Pulmonar Obstrutiva Crônica
Limite:
Humanos
País/Região como assunto:
Europa
Idioma:
Inglês
Revista:
Arch. bronconeumol. (Ed. impr.)
Ano de publicação:
2023
Tipo de documento:
Artigo
Instituição/País de afiliação:
County Hospital of Jarrio, Jarrio/Spain
/
Vall dHebron Research Institute (VHIR)+Spain
/
Oviedo University, Oviedo/Spain
/
Spanish Society of Pneumology and Thoracic Surgery (SEPAR)/Spain